Fabry  	Fabry  	 JJ	B-NP
disease 	disease 	 NN	I-NP
:  	:  	 :	O
perspectives  	perspectives  	 NN	B-NP
of  	of  	 IN	I-NP
urinary  	urinary  	 FW	I-NP
proteomics  	proteomics  	 FW	I-NP
Fabry  	Fabry  	 FW	I-NP
disease  	disease  	 FW	I-NP
( 	( 	 -LRB-	O
FD 	FD 	 NNP	B-NP
)  	)  	 -RRB-	O
is  	is  	 VBZ	O
an  	an  	 DT	O
X-linked  	X-linked  	 JJ	O
lysosomal  	lysosomal  	 JJ	B-NP
storage  	storage  	 NN	I-NP
disorder  	disorder  	 NN	I-NP
caused  	caused  	 VBN	O
by  	by  	 IN	O
mutations  	mutations  	 NNS	O
in  	in  	 IN	O
the  	the  	 DT	O
gene  	gene  	 NN	O
encoding  	encoding  	 VBD	O
the  	the  	 DT	O
lysosomal  	lysosomal  	 JJ	B-NP
enzyme  	enzyme  	 JJ	I-NP
a-galactosidase  	a-galactosidase  	 JJ	I-NP
A  	A  	 NNP	O
( 	( 	 -LRB-	O
a-GalA 	a-GalA 	 NNP	B-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
The  	The  	 DT	O
resulting  	resulting  	 JJ	O
deficiency  	deficiency  	 NN	O
in  	in  	 IN	O
a-GalA  	a-GalA  	 JJ	B-NP
activity  	activity  	 NN	I-NP
leads  	leads  	 VBZ	O
to  	to  	 TO	O
intra-lysosomal  	intra-lysosomal  	 JJ	B-NP
accumulation  	accumulation  	 NN	I-NP
of  	of  	 IN	I-NP
neutral  	neutral  	 JJ	I-NP
glycosphingolipids 	glycosphingolipids 	 NN	I-NP
,  	,  	 ,	O
mainly  	mainly  	 RB	O
globotriaosylceramide  	globotriaosylceramide  	 JJ	O
( 	( 	 -LRB-	O
Gb3 	Gb3 	 NNP	B-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
in  	in  	 IN	O
various  	various  	 JJ	O
organ  	organ  	 NN	B-NP
systems 	systems 	 NNS	I-NP
.  	.  	 .	O
As  	As  	 IN	O
a  	a  	 DT	O
consequence 	consequence 	 NN	O
,  	,  	 ,	O
a  	a  	 DT	O
multisystem  	multisystem  	 JJ	B-NP
disorder  	disorder  	 NN	I-NP
develops 	develops 	 VBZ	O
,  	,  	 ,	O
culminating  	culminating  	 VBG	O
in  	in  	 IN	O
strokes  	strokes  	 NNS	O
and  	and  	 CC	O
progressive  	progressive  	 JJ	B-NP
renal  	renal  	 NN	I-NP
and  	and  	 CC	O
cardiac  	cardiac  	 JJ	B-NP
dysfunction 	dysfunction 	 NN	I-NP
.  	.  	 .	O
Enzyme  	Enzyme  	 JJ	B-NP
replacement  	replacement  	 NN	I-NP
therapy  	therapy  	 NN	I-NP
( 	( 	 -LRB-	O
ERT 	ERT 	 NNP	B-NP
)  	)  	 -RRB-	O
offers  	offers  	 VBZ	O
a  	a  	 DT	O
specific  	specific  	 JJ	O
treatment  	treatment  	 NN	O
for  	for  	 IN	O
patients  	patients  	 NNS	O
affected  	affected  	 VBN	O
by  	by  	 IN	O
FD 	FD 	 NNP	B-NP
,  	,  	 ,	O
though  	though  	 IN	O
monitoring  	monitoring  	 VBG	B-NP
treatment  	treatment  	 NN	I-NP
is  	is  	 VBZ	O
hampered  	hampered  	 VBN	O
by  	by  	 IN	O
a  	a  	 DT	O
lack  	lack  	 NN	O
of  	of  	 IN	O
surrogate  	surrogate  	 JJ	O
markers  	markers  	 NN	O
of  	of  	 IN	O
response 	response 	 NN	O
.  	.  	 .	O
Furthermore 	Furthermore 	 RB	O
,  	,  	 ,	O
even  	even  	 RB	O
if  	if  	 IN	O
signs  	signs  	 NNS	O
and  	and  	 CC	O
symptoms  	symptoms  	 NNS	B-NP
of  	of  	 IN	O
the  	the  	 DT	O
disease  	disease  	 NN	O
become  	become  	 VBN	O
manifest  	manifest  	 VBN	O
in  	in  	 IN	O
childhood 	childhood 	 NN	O
,  	,  	 ,	O
its  	its  	 PRP$	O
diagnosis  	diagnosis  	 NN	O
is  	is  	 VBZ	O
often  	often  	 RB	O
delayed 	delayed 	 VBN	O
.  	.  	 .	O
Biomarkers  	Biomarkers  	 NNS	B-NP
that  	that  	 WDT	O
predict  	predict  	 VBP	O
disease  	disease  	 NN	B-NP
progression  	progression  	 NNS	I-NP
and  	and  	 CC	O
respond  	respond  	 VB	O
relatively  	relatively  	 RB	O
quickly  	quickly  	 RB	O
to  	to  	 TO	O
effective  	effective  	 JJ	O
therapy  	therapy  	 NN	O
may  	may  	 MD	O
be  	be  	 VB	O
useful  	useful  	 JJ	O
to  	to  	 TO	O
follow  	follow  	 VB	O
individual  	individual  	 JJ	B-NP
patients  	patients  	 NNS	I-NP
or  	or  	 CC	O
groups  	groups  	 NNS	O
of  	of  	 IN	O
patients 	patients 	 NNS	O
.  	.  	 .	O
Here  	Here  	 RB	O
we  	we  	 PRP	O
report  	report  	 VBP	O
the  	the  	 DT	O
use  	use  	 NN	O
of  	of  	 IN	O
2  	2  	 CD	O
different  	different  	 JJ	O
mass  	mass  	 NN	B-NP
spectrometry-based  	spectrometry-based  	 JJ	I-NP
proteomic  	proteomic  	 JJ	I-NP
techniques  	techniques  	 NNS	I-NP
to  	to  	 TO	O
identify  	identify  	 VB	O
disease-associated  	disease-associated  	 JJ	O
compositional  	compositional  	 JJ	B-NP
changes  	changes  	 NNS	I-NP
that  	that  	 WDT	O
can  	can  	 MD	O
be  	be  	 VB	O
used  	used  	 VBN	O
as  	as  	 IN	O
early  	early  	 JJ	O
biomarkers  	biomarkers  	 NN	B-NP
of  	of  	 IN	I-NP
the  	the  	 DT	I-NP
pathology 	pathology 	 NN	I-NP
,  	,  	 ,	O
as  	as  	 RB	O
well  	well  	 RB	O
as  	as  	 RB	O
for  	for  	 IN	O
monitoring  	monitoring  	 VBG	O
the  	the  	 DT	O
effectiveness  	effectiveness  	 NN	O
of  	of  	 IN	O
ERT 	ERT 	 NNP	B-NP
.  	.  	 .	O
To  	To  	 TO	O
this  	this  	 DT	O
purpose 	purpose 	 NN	O
,  	,  	 ,	O
we  	we  	 PRP	O
compared  	compared  	 VBD	O
the  	the  	 DT	O
renal  	renal  	 JJ	O
Fabry  	Fabry  	 JJ	O
urinary  	urinary  	 JJ	B-NP
proteome  	proteome  	 NN	I-NP
with  	with  	 IN	O
normal  	normal  	 JJ	O
( 	( 	 -LRB-	O
control 	control 	 NN	O
)  	)  	 -RRB-	O
urine  	urine  	 VBP	O
using 	using 	 VBG	O
,  	,  	 ,	O
respectively 	respectively 	 RB	O
,  	,  	 ,	O
2-dimensional  	2-dimensional  	 CD	O
gel  	gel  	 CD	O
electrophoresis  	electrophoresis  	 NNS	O
and  	and  	 CC	O
label-free  	label-free  	 JJ	B-NP
quantification 	quantification 	 NN	I-NP
.  	.  	 .	O
Our  	Our  	 PRP$	O
preliminary  	preliminary  	 JJ	B-NP
results  	results  	 NNS	I-NP
show  	show  	 VBP	O
that  	that  	 IN	O
the  	the  	 DT	O
urinary  	urinary  	 JJ	B-NP
protein  	protein  	 NN	I-NP
pattern  	pattern  	 NN	I-NP
of  	of  	 IN	O
affected  	affected  	 JJ	O
patients  	patients  	 NNS	O
can  	can  	 MD	O
be  	be  	 VB	O
easily  	easily  	 RB	O
distinguished  	distinguished  	 VBN	O
from  	from  	 IN	O
that  	that  	 DT	O
of  	of  	 IN	O
healthy  	healthy  	 JJ	O
subjects  	subjects  	 NNS	B-NP
both  	both  	 DT	O
qualitatively  	qualitatively  	 NN	O
and  	and  	 CC	O
quantitatively 	quantitatively 	 NN	O
,  	,  	 ,	O
thus  	thus  	 RB	O
encouraging  	encouraging  	 VBG	O
further  	further  	 JJ	O
studies  	studies  	 NNS	O
in  	in  	 IN	O
the  	the  	 DT	O
search  	search  	 NN	O
for  	for  	 IN	O
FD-specific  	FD-specific  	 JJ	B-NP
biomarkers  	biomarkers  	 NNS	I-NP
using  	using  	 VBG	O
this  	this  	 DT	O
proteomic  	proteomic  	 JJ	B-NP
approach 	approach 	 NN	I-NP
.  	.  	 .	O
